Nimble Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nimble Therapeutics, Inc. - overview
Established
2019
Location
Madison, WI, US
Primary Industry
Biotechnology
About
Based in Wisconsin, US, and founded in 2019, Nimble Therapeutics, Inc. operates as a biotech company that focuses on developing oral therapies for immune-mediated diseases. Nimble leverages its proprietary discovery engine to create therapies that replicate the benefits of established treatments. In December 2024, AbbVie agreed to acquire Nimble Therapeutics, Inc.
from Roche Venture Fund and Telegraph Hill Partners for USD 200 million in cash. Nimble Therapeutics specializes in advanced drug discovery technologies, focusing primarily on immunology and therapeutics. The company is dedicated to developing breakthrough medicines through its proprietary platforms, which facilitate the identification and optimization of novel therapeutic candidates. These technologies aim to address a variety of diseases by enhancing the therapeutic efficacy and safety profiles of drug candidates.
Nimble Therapeutics serves a diverse client base, which includes pharmaceutical companies and research institutions seeking to advance their drug development pipelines. Nimble Therapeutics generates revenue through strategic partnerships and collaborations with major pharmaceutical firms. The transaction structure typically involves B2B arrangements, where clients engage the company for its drug discovery services and technologies.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics
Website
www.nimbletherapeutics.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.